Home | Myotonic Dystrophy Foundation

Living in the Present Mike and Dean Sage have coping strategies for DM: it's all about family and living in the moment. Read more
February 28 is Rare Disease Day! MDF is proud to be a Rare Disease Day partner for the third year in a row. Read more about Rare Disease Day and our 2015 advocacy activities! Learn more
Making a difference in France and at home Alain Geille, one of the organizers for the IDMC-10 conference, shares his family's journey with DM as well as plans for the upcoming international meeting. Read more
Isis Launches Phase I/II Clinical Trial Isis Pharmaceuticals has initiated a clinical trial for ISIS-DMPKrx to treat patients affected by DM1. Learn More
A Story of Hope and Recovery "There are always challenges, but our daughter Zoé is really a trooper," says Sarah Berman. Read More

New Diagnosis? Start Here

Blog

RSS

February 17, 2015

Making connections through support groups

Leslie shares how joining and facilitating support groups has helped her navigate life with DM.

News

RSS

February 25, 2015

What is Orphan Drug Designation?

FDA's Orphan Drug Program is designed to encourage pharmaceutical companies to develop drugs for rare or 'orphan' diseases that might otherwise not be appealing to industry.

Read the Rest >

February 19, 2015

Healthy Heart Information for American Heart Month

February is American Heart Month, and MDF has partnered with Drs. Katharine Hagerman and Marianne Goodwin to highlight important research on cardiac issues in myotonic dystrophy for our readers

Read the Rest >

February 19, 2015

MDF Workshop Examines Clinical Trial Endpoints and Biomarkers

To support myotonic dystrophy drug development efforts, MDF held a science workshop in September 2014 at our annual conference. The workshop brought together more than 50 DM researchers and industry representatives from around the world to review where we are in the development of clinical trial endpoint measures for DM.

Read the Rest >